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Atherosclerosis has been studied in animals for almost a century, yet the events leading up to the rupture of an atherosclerotic
plaque (the underlying cause of the majority of fatal thrombosis formation) have only been studied in the past decade, due in
part to the development of a mouse model of spontaneous plaque rupture. Apolipoprotein E knockout mice, when fed a high-fat
diet, consistently develop lesions in the brachiocephalic artery that rupture at a known time point. It is therefore now possible to
observe the development of lesions to elucidate the mechanisms behind the rupture of plaques. Critics argue that the model does
not replicate the appearance of human atherosclerotic plaque ruptures. The purpose of this review is to highlight the reasons why
we should be looking to the apolipoprotein E knockout mouse to further our understanding of plaque rupture.
1.Introduction
Despite death rates from cardiovascular disease having fallen
in the United Kingdom since the 1970s (40% decrease for
peopleunder75inthepastdecade),diseaseofthecirculatory
systemaccountsforapproximately25%ofdeathsinunder75
year olds, and coronary heart disease is the leading cause of
death[1].Theunderlyingcauseofthemajorityofthisdisease
is atherosclerosis.
Atherosclerosis has been studied in animals since the
early1900s,startingwiththeworkofIgnatowski(reviewedin
[2]) despite atherosclerosis not being recognised as a major
disease at that time. Due to the recent increasing prevalence
of cardiovascular disorders, research into the disease is still
extremely important.
Inanidealworld,animalmodelsofatherosclerosiswould
replicate disease exactly as it is found in humans; however,
common sense tells us that this is not possible and a diﬀerent
approach is required. A good animal model will reproduce
the biochemistry of the disease but does not necessarily need
to produce an identical morphology. As long as the processes
that lead up to lesion formation are similar between animal
and human, and the model exhibits similar features of the
disease that make it a clinical risk (plaque rupture, mural
thrombosis, intraplaque haemorrhage), the model will yield
useful insights. A good example of this is the cholesterol-
fed rabbit model. Cholesterol-fed rabbits have been used in
atherosclerotic research for over 60 years and this model has
provided highly relevant clues as to how lesions develop in
humans. This research has been criticised because rabbits
are herbivorous and handle cholesterol in a way very unlike
humans.Thisdoesnotmeanweshouldignoretheﬁndings;it
means that we should interpret them cautiously, taking into
account the interspecies diﬀerences.
A good atherosclerosis animal model should enable us to
track changes in disease state over time, have similar lesions
(but not necessarily identical) to those in humans, and
employ animals which consistently develop atherosclerosis
in known locations, which breed rapidly, and which are
relatively inexpensive.
The general method of choosing an animal model of
atherosclerosis, even in present times, has been to use a
“top-down” approach, whereby disease features known to be
present in humans are required to be present in the animal
model. This has led to much sterile debate about whether
animal lesions look like human lesions. Anyone who has
looked at a good number of human lesions realises that they
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so it is not even possible to prescribe a lesion morphology
that the animal model should aspire to. It is time to abandon
the top-down approach and apply intellect to the problem.
Thisinessencemeansusingtheoppositemethod,a“bottom-
up” approach, to animal model selection. This applies
with particular force to animal models of plaque rupture,
which have suﬀered greatly from the narrow strictures of
top-down thinkers. A bottom-up philosophy means asking
whether a given animal model provides useful information
about the human disease; the appearance, genetic makeup,
dietary habits, size, and so on of the animal model are all
insigniﬁcantifthemodelenablesgenuineandusefulinsights.
The top-down approach became adopted for under-
standable reasons. The only source of information about
ruptured plaques was postmortem coronary artery speci-
mens, so all we had available was a snapshot of a disease that
may have been developing, even during its ﬁnal fatal phases,
for hours, days, or perhaps weeks. This leads to a number of
serious problems of interpretation.
(1) Patients are self-selecting—they have suﬀered a fatal
coronary event—and thus may not be representative
of the general population or even of patients with
nonfatal unstable plaques. This may bias any analysis
towards particular underlying mechanisms.
(2) The elapse of time between symptom onset and spec-
imen retrieval at postmortem will be accompanied
b yc h a n g e si nt i s s u ec o m p o s i t i o nw h i c hi tw o u l db e
desirable not to reproduce in the animal model.
(3) Within-subject temporal histopathological analysis is
impossible, and cohort-based between-subject analy-
s i si se x t r e m e l yd i ﬃcult.
(4) Post hoc interpretation involves speculation that is
not backed up by experimental veriﬁcation.
When, many years ago now, all we had to go on was a
series of such snapshots, it was reasonable to suggest that
an animal model should bear histopathological resemblance
to human unstable plaques. However, our ultimate goal is
not to make an animal model with perfect miniature plaque
ruptures; it is to make an animal model from which we
can learn how and why human plaques rupture, and that
can be used to test possible interventions to stop it from
happening. By this analysis, histopathology is of secondary
importance.Thishasbeenahardlessonforsomeintheﬁeld,
who continue to resist the force of this logic and demand
thatmouselesionsshouldlookjustlikehumanlesions—only
smaller. In this paper, we shall seek to show that an animal
model of plaque rupture does exist, that it has provided
useful and meaningful insights into human disease, and
that top-down thinking continues to dog our attempts to
bring experimental pathology in atherosclerosis research up
to date.
2. What Is Atherosclerosis?
The term atherosclerosis was coined in 1940 by F´ elix
Marchand [3] as it describes the two constituent regions of
plaques very accurately: ath´ er´ e in Greek meaning gruel or
porridge and signifying the soft lipid-ﬁlled core and sclerosis
implying hardening and referring to the hard ﬁbrotic cap
that separates the blood from the thrombogenic material
within the lesion [4]. Interestingly, atherosclerosis is not just
a disease of modern civilizations. Egyptian mummies of high
priestsandpriestessesfrom1580–527BChavebeendissected
and shown to have lesions similar to modern day man.
Atherosclerosis in these mummies was described as follows:
“the disease being characterised by marked degeneration of
the muscular coat and of the endothelium. These diseased
patches, discrete at ﬁrst, fuse together later, and ﬁnally form
comparatively large areas of degenerated tissue, which may
reach the surface and open out into the lumen of the tube”
[5].
Atherosclerosis is a chronic disease of the intimal lining
of medium to large systemic arteries. In healthy arteries,
o x y g e n a t e db l o o dc a nf r e e l yt r a v e la r o u n dt h eb o d yt o
the organs and extremities, maintaining a healthy system;
however, in atherosclerotic arteries the ﬂow of blood can
be seriously compromised due to thickening of the intima.
The disease itself does not always cause death. In the earlier
stages, the blood vessels can remodel to maintain the luminal
area (as shall be discussed later) and counteract the intimal
thickening. If the lesion expands at a rate greater than the
outward remodelling of the vessel, then the ﬂow of blood
will decrease causing, for example, angina (heart pain).
However, more signiﬁcant clinical consequences occur if
the lesion develops into a ﬁbrous plaque (advanced lesion)
that ruptures. This rupturing brings the blood into contact
with the thrombogenic core of the lesion precipitating a
thrombus that in itself could severely restrict the lumen
[35]. It has been shown that a thrombus over a stenosis
in the canine coronary arteries can cause a reduction in
vessel resistance (caused by decreased blood ﬂow and/or
increased pressure gradient) downstream of the plaque [6].
Another potential consequence of thrombosis formation is
the shedding of emboli that break oﬀ and become lodged in
smaller vessels downstream, completely occluding ﬂow and
leading to myocardial infarction, if in a coronary artery, or
stroke, if in a carotid. Approximately 75% of the thrombi
responsible for acute coronary syndromes are precipitated
by rupture of an atherosclerotic plaque [7]. Fortunately,
not all plaque ruptures lead to vessel-occluding thrombosis.
The rupture can be clinically silent and heal itself by the
accumulation of smooth muscle cells at the site of rupture
leading to secretion of ﬁbrous extracellular matrix [8, 9],
lending a striated appearance to the plaque, so-called buried
ﬁbrous caps (Human [10, 11], Mice [12]). Despite healing
the rupture, this event can lead to luminal stenosis by
increasing plaque growth [9, 11].
3. The MouseAs a Modelof
Atherosclerotic Plaque Rupture
Mice are highly resistant to atherosclerosis. In the 1960s,
a diet-induced mouse model was developed by feeding the
C57BL/6 strain a diet containing 30% fat, 5% cholesterol,Journal of Biomedicine and Biotechnology 3
and 2% cholic acid leading to the development of atheroscle-
rosis. The downside to this diet was that it was highly toxic
and the mice lost weight and tended to develop morbid
respiratory infections [13]. This diet was modiﬁed in 1990 to
contain15%fat,1.25%cholesterol,and0.5%sodiumcholate
[14] leading to lesion development without the toxic side
eﬀects.Thesamegroupalsodeterminedthattherewerelarge
diﬀerences in strain susceptibility to lesion development,
providing strong evidence for genetic composition as a risk
factor for atherosclerosis.
4.ApolipoproteinE
Apolipoprotein E (ApoE) is a lipoprotein which plays a key
protective role in atherosclerosis. All cells and organisms
use lipoproteins to move hydrophobic, water-insoluble lipid
molecules through the aqueous blood and tissue lymph
environment. Lipoproteins consist of apolipoproteins, phos-
pholipids, cholesterol, triacyclglyerols, and cholesteryl esters
and it is these that deﬁne the particle’s buoyant den-
sity and enables their separation into four major classes:
high-density lipoprotein, low-density lipoprotein, very low-
density lipoprotein (HDL, LDL, and VLDL, resp.), and
chylomicrons. Discovered in the 1970s [15, 16], apoE is an
arginine-rich protein found in chylomicrons, chylomicron
remnants, VLDL, and some isotypes of HDL [17]. It is
produced in various tissues including brain, spleen, lung,
ovaries, adrenal gland, kidney and muscles, but it is in the
liver where the majority found in plasma is synthesised [18].
Recognition sites for LDL receptors (LDL-R) and LDL-R
related proteins are found in an amino-terminal region of
apoE, thus facilitating the hepatic uptake of lipoproteins and
maintaining plasma cholesterol homeostasis [19].
ApoE has numerous antiatherogenic roles, predomi-
nantly due to its actions on the lipid metabolism pathway
(foranin-depthreviewthereaderisdirectedto[19]).Brieﬂy,
it is involved in the hepatic uptake and subsequent degra-
dation of lipoproteins through the LDL-R on parenchymal
liver cells, clearance of chylomicron remnants through the
action of LDL-R related proteins, the stimulation of hepatic
VLDL and TG production, reverse cholesterol transport
(the process whereby excess cholesterol is transported via
HDL to the liver for excretion in bile) and activation
of enzymes, such as hepatic lipase and cholesteryl ester
transfer protein, involved in lipoprotein metabolism. ApoE
also has antiatherogenic eﬀects not involved directly in lipid
metabolism which include inhibition of LDL oxidation [20],
platelet aggregation [21], smooth muscle cell proliferation
[22], endothelial cell proliferation [23], and inhibition of T-
lymphocyte activation and proliferation [24, 25].
5. ApoE Knockout Mouse Model
In humans, decreased expression of apoE caused by some
types of genetic disease (Type III hyperlipoproteinaemia
associated with familial apolipoprotein E deﬁciency) leads
to an altered lipid proﬁle and an increase in the prevalence
of atherosclerosis in these patients [26, 27]. In 1992,
an apoE knockout (apoE
−/−)m o u s em o d e lo fs p o n t a -
neous atherosclerosis was developed [28] that would enable
researchers to track the progression of the disease over a
manageabletimescale.Cruciallytherewasnoeﬀectonfertil-
ity or birth weight when compared to normal mice, and they
appeared to be healthy. In the study of atherosclerosis, the
haemodynamics of the cardiovascular system are important
as they have implications for such parameters as the shear
stress of the blood ﬂowing over the arterial wall, as regions of
lower shear stress are thought to induce lesion development
[29–32]. When compared against C57BL/6 wild-type mice,
apoE knockout mice have a normal heart rate and blood
pressure, but they have been shown to have elevated pulse
wave velocity, elevated aortic and mitral ﬂow velocity,
alterations in aortic acceleration suggestive of increased
pulse wave reﬂection, decreased haematocrit, and increased
heart-to-body weight ratio (decreased body weight, cardiac
hypertrophy) [33]. Homozygous apoE knockout mice fed a
chow diet have been shown to have plasma cholesterol levels,
at 6 weeks of age, that are approximately ﬁve times greater
thanthoseinnormalwild-typemice.However,heterozygous
knockouts have cholesterol levels similar to wild-type mice
[34].
6. PlaqueVulnerability
6.1. Detection and Quantiﬁcation of Plaque Rupture. Athero-
sclerotic plaques can be divided into two distinct types;
those that rupture (vulnerable, or unstable, phenotypes) and
thosethatdonot(stablephenotypes).Basedonretrospective
human autopsy studies comparing intact and disrupted
plaques, it has been reported that vulnerable plaques are
characterised by a large lipid-rich core occupying more than
40% of the plaque’s total volume (although 50% has been
suggested elsewhere [35]), covered by a thin ﬁbrous cap
(<100μm thick), with extensive macrophage inﬁltration but
very few smooth muscle cells [36].
Human studies have shown that ruptured and vulnerable
plaques have the following pathologic features (summarised
in [37]):
(1) positive (i.e., outward) remodeling,
(2) a ﬁbrous cap less than 100μm (and perhaps less than
65μm) at its minimum thickness,
(3) macrophageinﬁltration(especiallyinthethinﬁbrous
cap).
(4) a large lipid/necrotic core often containing haemor-
rhage and/or calciﬁcation,
(5) speckled or diﬀuse calciﬁcation,
(6) abundant intraplaque vasa vasorum and/or haemor-
rhage.
A plaque rupture can be deﬁned as a disruption of the
ﬁbrous cap accompanied by intrusion of erythrocytes into
the plaque itself [12]. This deﬁnition enables ruptures to be
distinguished from artefactual damage during histological
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which is deﬁned as loss of endothelium, leading to thrombus
formation, without any associated ﬁssure or rupture [38].
From a very young age, lipid permeates into the arterial
wall forming what is known as a fatty streak, made up of
T-lymphocytes and lipid-rich macrophages. Clinically silent
fatty streaks are present in most people, even without the
inﬂuence of external risk factors, and are thought to be a
protective response to potential damage to the endothelium
and underlying smooth muscle cells [39]. These early lesions
precede the development of intermediate lesions which are
made up of further layers of macrophages and smooth
muscle cells, which themselves go on to become complex
lesions called ﬁbrous plaques [39]. It is these which can
go on to rupture with potentially serious consequences.
It has been reported that most acute coronary events
are precipitated by rupture of an atherosclerotic plaque
[40]. However, most plaque ruptures do not result in
any symptoms [11]. One possibility for this unusual phe-
nomenon is that plaque ruptures can heal, and the increased
lesion size can be accommodated by vessel remodelling
[41].
7. MouseModelofSpontaneousPlaqueRupture
Up until 2001 there were no models of spontaneous plaque
rupture in animals. Previous models relied on artiﬁcially
inducing the plaques to rupture by acute insult. An early
example is the cholesterol-fed rabbit injected parenterally
with Russell viper venom and histamine, which leads to
acute plaque disruption in ∼30% of animals [42]. Another
approach involves balloon catheter-injured cholesterol-fed
rabbits with an implanted balloon catheter in the thoracic
aorta [43]. The balloon is left in place for at least 1 month
so an atherosclerotic lesion can develop around it, before
being inﬂated thus disrupting the atherosclerotic lesion and
precipitating thrombosis. A third model made use of the
apoE knockout mouse and involved compression injury
using blunt forceps applied to atheromatous lesions in the
abdominal aorta [44]. This technique resulted in a third of
the animals showing evidence of intraplaque haemorrhage
within disrupted plaques and plaque-associated luminal
thrombosis. A similar technique was used by Bentzon et
al. [45] whereby a microsurgical needle was inserted into
the luminal surface of advanced plaques, leading to cap
disruption. A further approach has been to use apoE
knockout mice with atheromatous lesions induced by an
externally placed silastic collar [46], and then to transfect
these with an adenovirus expressing the tumour-suppressor
protein p53 [47]. At one day posttransfection, increased
apoptosis is evident in the cells of the ﬁbrous cap and
cap thinning is seen at later time points. These attenuated
ﬁbrous caps undergo rupture in 40% of animals after pressor
challenge with phenylephrine [47]. Whilst these models are
extremely valuable as tools for studying events after rupture,
they do not enable us to observe the events leading up to,
and triggering, a spontaneous rupture (smooth muscle cell
apoptosis, macrophage accumulation, lipid accumulation
and loss of extracellular matrix) and are more a model of
postrupture thrombosis.
The brachiocephalic, or innominate, artery is a very
short, narrow vessel (∼2mm long with a diameter of ∼
0.5mm in mice) emanating from the top of the aortic
arch and branching into the right subclavian and right
common carotid arteries. Importantly, it reliably develops
complex plaques. Studies of apoE knockout mice aged 42–
54 weeks fed a normal chow diet showed a high frequency of
intraplaque haemorrhage and ﬁbrotic conversion of necrotic
zones and loss of ﬁbrous cap tissue [48]. Although ﬁbrous
cap thinning was observed, neither plaque rupture nor
thrombosis was identiﬁed. The ﬁndings of an acellular
necrotic core, intraplaque haemorrhage, and erosion of core
through to lumen suggest a resemblance to plaque erosion
with thrombosis.
The elusive spontaneous plaque rupture was ﬁnally
observed having fed apoE knockout mice a high-fat diet
containing 21% pork lard and 0.15% cholesterol for up to
14 months [49]. Plaque ruptures were found to occur in
the brachiocephalic artery. Ruptures occur in the proximal
150μm of the vessel, so there is tight anatomical localisation
of the phenomenon making comparison of data across
studies straightforward [41]. Observations of serial sections
of the brachiocephalic artery suggest that plaque ruptures
are rarely more than 60μmi nl e n g t h[ 50], whereas in
human coronary arteries the average tear length is 1.9mm
[51]. Lesions that rupture in the brachiocephalic artery
h a ds e v e r a lc o m m o nf e a t u r e sa c r o s sm i c e[ 49]. They were
relatively small, lipid-rich, and globular and were overlying
large advanced lesions. The ruptured lesions had intraplaque
haemorrhage as evidenced by the presence of erythrocytes
and were associated with luminal thrombus formation.
8.Mice versusHumans
Most human atherosclerosis is the result of a lifetime of
multiple risk factors such as tobacco smoking, elevated
cholesterol levels, elevated blood pressure, unhealthy diet,
age and genetic susceptibility. It is not possible to replicate all
of these in a mouse model of atherosclerosis, but does that
mean that these models should be ignored?
Atherosclerotic lesions do not occur randomly in the
human vasculature but are localised at bends, bifurcations,
and T-junctions [31]; these are all regions with altered wall
shear stress (the frictional force of the blood ﬂowing across
the endothelium). An important feature of atherosclerosis
is that it occurs in systemic arteries, but never in veins
or pulmonary arteries, suggesting that local haemodynamic
factors, wall properties, and pressure play a critical role in
lesion formation. Mice develop lesions in a similar manner,
suggesting that the arterial wall is aﬀected in a similar
manner despite a 20-fold diﬀerence in the actual wall shear
stress between species [52, 53].
Lesionsinmicearelocatedatregionsofloworoscillatory
shear stress [54] and in particular in the aortic root,
brachiocephalic artery, lesser curvature of the aortic arch,
and the branch points of the left common carotid and left
subclavian arteries, and to a lesser extent in the descending
thoracic aorta. Recent research has shown that the geometry
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located in mice [55, 56]. Diﬀerences in aortic arch geometry
are not just a feature of mice and occur in humans as
well [57]. The geometry of blood vessels, and in particular
the angle that a daughter vessel branches from the parent,
has been linked to altered intimal and medial thickness
[58].
Perhaps understandably, the mouse as a model of
atheroscleroticplaquerupturehasbeenquestionedastohow
well it replicates the disease in humans due to diﬀerences
in geometry. If we look at basic physiological properties,
there are obvious diﬀerences. Mice are about 3000 times
smaller than humans. In mammals, cardiac mass varies
in direct proportion to body mass (so-called “isometric”
scaling) [59] leading to a ventricular stroke volume that also
scales isometrically [60]. The heart rate has been shown to
scale allometrically and follows a quarter power law (heart
beat frequency ∝ body mass to the power −0.25) [61]. On
top of this, wall shear stresses have been predicted to be
20-fold higher in mice than humans [53]. Whilst human
coronary arteries are typically 2.4mm in radius with a wall
thickness of 0.76mm [62], the mouse brachiocephalic artery
is ∼0.36mm in radius with a wall thickness of 0.04 mm [12].
This thereforeleads to very diﬀerent tensile forceson the cap.
Superimposed thrombosis is rarely seen in apoE knock-
out mice [63]. However, this is not a reason to rule out the
mouseasagoodplaquerupturemodel.Thelackofthrombus
could simply be a consequence of pressure perfusing the
mouse vessel before removal of tissue. This could cause any
thrombus present to be washed away, preventing it from
being seen in subsequent analysis. Perhaps a more likely
explanation is that thrombi are cleared very rapidly by the
ﬁbrinolytic system in mice. Plasma levels of plasminogen
activator inhibitor (PAI-1) are from 5- to 12.5-fold lower
in mice than humans, whereas ﬁbrinogen and tissue-type
plasminogen activator (tPA) concentrations are similar [64].
This suggests that the ﬁbrinolytic balance in mice is shifted
more towards enhanced lysis. The volume and surface area
of a thrombus over a human plaque would be roughly 200-
fold and 30-fold greater, respectively, than in a mouse. Some
human coronary thrombi may be present for months [65],
so even if we conservatively assume equal rates of ﬁbrinolysis
then mouse thrombi will be resolved within a few days. This
suggeststhatthereisonlyarelativelysmalltimewindowafter
a mouse plaque rupture during which a thrombus will be
present. Despite superimposed thrombosis rarely being seen
in apoE knockout mice, intraplaque haemorrhage is seen in
the majority of plaque ruptures [49]. In human coronary
plaquesthatrupture,thereareagreaternumberofneovessels
(vasa vasorum) running through the plaque that may lead to
intraplaque haemorrhage [66], and this has also been seen
in mice [67]. However, haemorrhage has also been observed
in plaques without vasa vasorum, including plaques in the
brachiocephalic artery, suggesting that luminal blood must
h a v ee n t e r e dv i aas u r f a c ed e f e c t[ 68].
It was previously assumed that smooth muscle cells
found in plaques were derived from local medial or intimal
smooth muscle cells within the vessel wall. However, a
study looking at postmortem human tissue found that
∼20% of smooth muscle cells originated from bone marrow
(which had been transplanted for haematological disease),
suggestingthatplaquesgetsomeoftheirsmoothmusclecells
from the circulating blood [69]. In mice, the original theory
appears to stand, in that tracking marker-labelled smooth
muscle cells were not found in the plaques, only smooth
muscle cells from the local wall [70]. It is currently unclear
whetherthesearetruediﬀerencesbetweenspeciesorwhether
therearesimplymethodologicaldiﬀerenceswhichcouldlead
to the diﬀerent outcomes.
Should these diﬀerences stop us using the mouse as
a model of atherosclerosis? Perhaps somewhat surprisingly
there are also important similarities between mice and men.
Murine systolic and diastolic blood pressures (125 and
90mmHg, resp.) are similar to those found in the human
coronary arteries [71]. Doppler ultrasound studies show that
the average peak aortic root blood velocities are 1.04m/s
in mice [72] and 1.03m/s in humans [73]. The location
of atherosclerotic lesions appears fairly uniform across all
species, implying a role of haemodynamic properties, and in
particular implicating regions of lower shear stress resulting
in increased lipid deposition [29–32].
9.VesselRemodelling
It is widely accepted that arterial dimensions change
throughout life, even in the absence of disease, as part of a
homeostatic system that maintains a constant ﬂow of blood
throughthevessels.Inthepresenceofatheroscleroticlesions,
it has been observed that radial enlargement of vessels
(outward remodelling) can compensate for the obstructive
bulk of the lesion, thus reducing the degree of ﬂow-reducing
stenosis in the vessel [74]. However, in some cases the lumen
cross-sectional area can be decreased without an increase in
lesion size (inward remodelling), suggesting that the arterial
wall actually shrinks, increasing the degree of stenosis [75,
76].
The degree of stenosis caused by a plaque is an important
factor when looking at the mechanics of plaque rupture,
in part shown by Poiseuille’s equations and Laplace’s law.
There are three main factors that determine resistance to
blood ﬂow within a vessel: blood viscosity, vessel length,
and most importantly physiologically, vessel diameter (or
radius). Poiseuille found that the resistance to ﬂow between
two points is inversely proportional to the tube radius raised
to the fourth power, r4 [77] showing that small decreases in
lumen diameter caused by, for example, an atherosclerotic
plaque, will greatly increase the resistance and frictional
forces of the blood ﬂowing over the plaque. However, using
Laplace’s law, it can be shown that for two vessels each
with ﬁbrous caps of the same tensile strength, caps covering
mildly or moderately stenotic plaques compared to more
severe stenotic plaques, the former will be exposed to a
greater circumferential strain and as such be more prone to
rupture [78]. Laplace’s law shows the relationship between
circumferential wall stress, the radial wall stress, the radius
of the vessel, and the thickness of the wall and suggests
that high circumferential stress can develop in thin ﬁbrous
caps, possibly causing the mechanical failure of the plaque
[79].6 Journal of Biomedicine and Biotechnology
A recent study using human computationally simulated
cross-sectional plaque morphologies (acquired by IVUS),
mimicking diﬀerent stages and variations in atherosclerotic
lesion growth, looked at the eﬀects of anatomical plaque
features on peak cap stress, a known predictor of rupture
in human lesions [80]. It was found that at the early stages
of positive remodelling, lesions were more prone to rupture
and that, in addition to ﬁbrous cap thickness, necrotic core
thickness rather than area, was critical in determining plaque
stability.
As t u d yb yJ a c k s o n[ 41] observing lesions in the bra-
chiocephalic arteries of apoE knockout mice fed high-fat
diet for up to a year showed that an increase in plaque
area leads to an increase in vessel area, as the vessels
remodel to accommodate the increased plaque burden
(the vessels expansively remodel), as is the widely held
view. Strain-matched, wild-type mice fed the same high-
fat diet did not develop atherosclerosis and did not exhibit
the same expansive remodelling showing that this is not
simply a phenomenon associated with ageing and growth.
The plaques were subsequently analysed based on their
vulnerability (stable versus unstable) and a diﬀerent story
emerged. Stable plaques increased in area, but the vessel
area remained the same, leading to a decreased lumen size.
Unstable plaques also increased in area at the same rate
as in the stable lesions, but interestingly the vessel area
increased and the vessel expansively remodelled. Therefore,
plaque growth itself cannot be causing the increased rate of
vessel expansion in the brachiocephalic artery, supporting
the ﬁnding that there is vessel expansion even in the absence
of plaque (there were no diﬀerences in vessel expansion
betweenmaleandfemalemice)[41].Thequestioniswhether
plaque rupture is causing expansive remodelling, or whether
expansive remodelling is causing the rupture. The ﬁnding
that even in the absence of plaques remodelling still occurs
supports the latter explanation. When the vessel expansively
remodels, the ﬁbrous caps of plaques are placed under
tension and when this force overcomes the cap strength a
rupture ensues. The actual rupture event, if it were not for
the potentially detrimental thrombotic consequences, could
beseenasbeneﬁcialtothepatientasitallowsthelumentobe
restored and maintained, and this could explain why plaque
rupture can be asymptomatic.
Further evidence for this controversial hypothesis can
be found in studies using HMG-CoA reductase inhibitors.
Statins are used to treat humans as they have been shown
to lower plasma cholesterol levels and cause regression of
atheroma [81]. Their eﬀects include improving endothelial
function, modulating inﬂammatory responses, preventing
thrombus formation, and improving plaque stability [82].
This potential eﬀect on plaque stability in humans led to
statins being investigated in mice. High-fat diet-fed mice
treated with pravastatin showed a reduced incidence of
plaque rupture coinciding with a 5-fold increase in ﬁbrous
cap thickness. However, it did not inﬂuence overall rates of
vessel remodelling, but signiﬁcantly increased the amount
of vessel expansion and the time between plaque ruptures
[41].
1 0 .W h e r eDoe st h eA po EK n oc k o u tM o us e
Model of PlaqueRuptureStand Today?
There has been some resistance to the notion that mice
suﬀer spontaneous rupture of atherosclerotic plaques. This
has been articulated in press primarily by a small group of
dissenting scientists [68, 83]. Their criticisms centre on the
following points.
(1) Deﬁnitions of plaque rupture as used in clinical
histopathology are not satisﬁed by murine plaque
ruptures.
(2) Murineplaquerupturescouldbetheresultofdamage
during postmortem tissue processing.
(3) The structures described as healed plaque ruptures in
mice are in fact nothing more than layering of the
plaque resulting from episodic growth.
Let us dispose of these one by one—and, we hope, this
time once and for all. They have already been carefully
considered and disproved [50, 84], but it appears that the
message is failing to be appreciated and the standard view
of mouse models of spontaneous plaque rupture is that they
are controversial. They are not controversial at all. Here is
why.
(1) Deﬁnitions of plaque rupture as used in clinical
histopathology are not satisﬁed by murine plaque
ruptures.
The issue of deﬁnition is a classic example of “top-
down” thinking, which proposes that mouse plaque
ruptures cannot be useful unless they look just like
human plaque ruptures. One key part of this was
the insistence for a long time that mouse plaque
ruptures had to have an overlying thrombus to
even be considered as genuine ruptures. We have
pointed out many times how confused this idea is.
Thrombosisisthesecondaryconsequenceofrupture,
not the rupture itself, so there is no ap r i o r ireason
why it should be faithfully modelled; furthermore,
murinethrombiaretinybuttheirﬁbrinolyticsystems
are very eﬀective, so thrombi may form but be lysed
before the vessel is harvested. We note that in studies
by the authors of these dissenting articles that in their
ownstudiesofdisruptedmurineplaques,theydonot
seepersistentthrombosis[45].Perhapsthisiswhythe
formerly inﬂexible requirement for thrombosis over
disrupted murine plaques has now been dropped
[68]. This is the correct position, because overlying
thrombus is not a cardinal feature of murine plaque
rupture.
(2) Murineplaquerupturescouldbetheresultofdamage
during postmortem tissue processing.
This is a testable hypothesis because it leads to
predictions that can be addressed experimentally.
The ﬁrst prediction is that defects in the ﬁbrous cap
will not be accompanied by ingress of blood cells
into the plaque. The operating deﬁnition of acuteJournal of Biomedicine and Biotechnology 7
murine plaque rupture that we have always used is “a
visible defect in the cap accompanied by intrusion of
erythrocytes into the plaque below it” [12]. We have
reported on the presence of ruptures that fulﬁl this
deﬁnition in the proximal brachiocephalic arteries of
maleapoEknockoutmicefrom5weeksoffat-feeding
onwards [85]. After 8 weeks of fat-feeding, 62% of
173 animals exhibited acute plaque rupture in the
brachiocephalicartery.Therefore,thehypothesisthat
handling artifacts may be misinterpreted as plaque
disruptions occurring during life can be shown not
to hold true, as dozens of ruptures have been shown
to be accompanied by the insudation of formed
elements of blood, which can only happen during
life. A second prediction is that the rate of incidence
of defects in the ﬁbrous cap will be similar at all
time points once plaques have developed, because
handling injuries are not related to the stage of
development of the plaque. As described above,
published data show that the incidence of defects in
the ﬁbrous cap varies markedly and signiﬁcantly at
diﬀerent time points. For example, the incidence falls
from 62% to 30% within the course of a week (P =
.0005). Therefore, this prediction also fails to hold
true: defects in the ﬁbrous cap occur at a rate that is
diﬀerentatdiﬀerenttimepoints.Thethirdprediction
based on the handling artifact hypothesis is that the
rate of incidence of defects in the ﬁbrous cap will be
independent of drug treatment, because treatments
administered to mice during life cannot inﬂuence
the inﬂiction of postmortem handling damage on
plaques. However, the incidence of acute plaque rup-
ture is statistically very highly signiﬁcantly reduced
by treatment with pravastatin: after 40 weeks of high-
fat feeding, continuous treatment with pravastatin
reduced the incidence of acute plaque rupture by
86% (P<. 0001) [85]. Even when treatment was
delayeduntil16weeksofhigh-fatfeedinghadalready
elapsed, acute plaque ruptures occurred 56% less
frequently (P<. 0001). It is particularly notable that
the latter eﬀect was achieved in the absence of any
signiﬁcant eﬀect on plaque size (−6%). Therefore,
this third prediction also fails, because defects in the
ﬁbrous cap occur at a rate that can be inﬂuenced by
pharmacological treatment and this can be achieved
independently of any eﬀect on plaque size.
(3) The structures described as healed plaque ruptures in
mice are in fact nothing more than layering of the
plaque resulting from episodic growth.
This is another testable hypothesis. The ﬁrst pre-
diction is that buried ﬁbrous caps should occur
with equal frequency at all anatomical sites that
develop suﬃciently large plaques. This is because a
manifestation of standard plaque expansion should
not be distributed in any anatomically dependent
fashion and should not be related to the presence or
absence of acute plaque rupture at that site. Acute
plaque ruptures are not observed, in our very long
experience, in the retrovalvular lesions of the apoE
knockout mouse aortic sinus. However, these plaques
are very large—about twice the size of the plaques
in the nearby proximal brachiocephalic artery after
9 months of fat-feeding. The incidence of buried
ﬁbrous caps in plaques in the aortic sinus in a series
of 28 fat-fed apoE knockout mice was zero. In the
brachiocephalic artery plaques of the same 28 mice,
there were 35 such structures (P<. 0001). Therefore,
the incidence of buried ﬁbrous layers is signiﬁcantly
related to the occurrence of acute plaque rupture but
not to plaque size, and the prediction is not borne
out by the available data. The second prediction
is that the presence of ﬁbrin in the plaque should
be independent of the presence of a buried ﬁbrous
cap, because ﬁbrin would be a sign of thrombosis
whereas buried ﬁbrous caps are hypothesised to be
part of normal plaque development. We have shown
that immunoreactive ﬁbrin is present at the sites
of buried ﬁbrous caps in apoE knockout mouse
brachiocephalic arteries, using a goat polyclonal
antibody that is not reactive with ﬁbrinogen. In a
series of 50 male apoE knockout mice that had been
fat-fed for 8 weeks, the presence of ﬁbrin (as assessed
by bright red staining with Masson’s trichrome) was
signiﬁcantly associated with the presence of a buried
ﬁbrous cap. Of the 50 mice, 23 had buried ﬁbrous
caps at this site, and 19 of these 23 plaques were
positive for ﬁbrin. Amongst the 27 mice with no
buried ﬁbrous caps, 4 were stained positively for
ﬁbrin (P = .000001). We conclude that ﬁbrin accu-
m u l a t i o na ts i t e so fb u r i e dﬁ b r o u sc a p si sv e r i ﬁ e db y
speciﬁc antibody staining, and by tinctorial criteria it
isstatisticallyveryhighlysigniﬁcantlyassociatedwith
the presence of buried ﬁbrous caps. This means that
thesecondpredictionisalsocontradictedbythedata.
The third prediction that ﬂows from the hypothesis
that buried ﬁbrous caps are part of normal plaque
development in mice is that their incidence should
covary with plaque size. Studies in apoE knockout
animalstreatedwithpravastatinorwithanadditional
null mutation to the cathepsin S gene [86] show that
plaque size and the number of buried ﬁbrous caps
can be modulated independently. When pravastatin
treatment commenced after advanced plaques had
already developed, the formation of buried ﬁbrous
caps was reduced by 36% (P<. 0001) but there
was no signiﬁcant eﬀect on plaque size (−6%). In
the case of cathepsin S, the incidence of buried cap
formation normalised to plaque size was reduced
by 37% (P = .044) in the double knockouts.
Thus the incidence of buried ﬁbrous caps can be
modulatedindependentlyofanyeﬀectonplaquesize,
and the data are once again at variance with the
prediction.
Thus the objections to a mouse model of atherosclerotic
plaquerupturehaveallbeentestedandcanbediscardedwith
extraordinarily high levels of statistical conﬁdence.8 Journal of Biomedicine and Biotechnology
11. Conclusion
The fat-fed apoE knockout mouse proximal brachiocephalic
artery model is an excellent test-bed for potential therapies
for plaque rupture and should yield useful insights into
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